GE HeatlhCare launches new advanced digital X-ray system
July 21, 2025
GE HealthCare (Nasdaq: GEHC)+
today announced the commercial launch of its advanced floor-mounted digital X-ray system.
GE HealthCare (Nasdaq: GEHC)+
today announced the commercial launch of its advanced floor-mounted digital X-ray system.
Accurate removal of tumors is the most critical aspect of cancer surgery, yet it remains a significant challenge in clinical practice. In breast cancer, for example, the positive margin rate—where cancer cells remain at the surgical boundary—can reach up to 35%, often requiring reoperation and increasing the risk of recurrence.
A 3D paper-based analytical device (3D-osPAD) with in situ gold signal amplification enables one-step, highly sensitive detection of anti-IFN-γ autoantibodies within 10 minutes, showing 10-fold improved sensitivity and high clinical accuracy for adult-onset immunodeficiency.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited condition that can lead to kidney failure. Being able to accurately predict how the disease will progress is very important for selecting the right treatments and providing effective patient counseling.
In a new study published in Cancer Immunology Research, scientists at the Icahn School of Medicine at Mount Sinai have developed a novel method to generate billions of rare immune cells known as conventional type I dendritic cells (cDC1s), potentially paving the way for a new class of off-the-shelf cellular cancer vaccines.
Spirair announced today that the FDA granted 510(k) clearance for its TurbAlign bioabsorbable implant device.
Boston Scientific (NYSE: BSX)+
has received expanded FDA approval for the use of its Watchman FLX and Watchman FLX Pro devices.
NDA for TAR-200 targets high-risk non-muscle invasive bladder cancer, highlighting potential to transform treatment for patients unresponsive to BCG therapy
Tiny fat bubbles carrying gene therapy have successfully repaired DNA in the lungs and liver of animals with alpha-1 antitrypsin deficiency—a promising leap toward treating humans with this rare inherited disease.
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to “wake up” the immune system against cancer.